Canada Markets open in 28 mins

Defence Therapeutics Inc. (DTCFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.6900+0.0100 (+0.60%)
At close: 12:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.6800
Open1.6900
BidN/A x N/A
AskN/A x N/A
Day's Range1.6900 - 1.6900
52 Week Range1.6500 - 6.4078
Volume500
Avg. Volume152
Market Cap60.78M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination

    Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its AccumTM-linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix. Various strains

  • Newsfile

    RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

    The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to prote

  • Newsfile

    Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

    Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vac